AMRX at 52-Week High in Stage 2 Uptrend, No Base Formed

Posted on by Eben@CANSLIM Research
AMRX stock profile infographic with daily candles, 20, 50 and 150-day simple moving averages and volume, Stage 2 (Advancing), as of October 31, 2026 at 17:58 - CANSLIM Research
AMRX closed at 21.51, sitting at its 52-week high with a perfect 8 of 8 trend template score and price holding above a rising 30-week moving average. The stock is in a confirmed Stage 2 advance, though no base or VCP has formed given the move is only one week old, and volume is running 130 percent of the 50-day average. Sentiment is bullish, reflecting an offensive setup with the trend intact and the stock within striking distance of new highs.

AMRX   Daily · data to 2026-10-30 close · 20 SMA 50 SMA 150 SMA
Frozen at publication – this chart does not move. Open live chart on TradingView →

SECTORHealthcareINDUSTRYDrug Manufacturers – Specialty & GenericStage 2Weinstein stage
Data to US close: Fri 30 Oct 16:00 ET = Sat 31 Oct 04:00 HKTCreated: Sat 31 Oct 17:58 HKT = 05:58 ET

Inside the Full Report

  • 🔒
    Stage AnalysisWhy the stock sits in this stage and what would change that
  • 🔒
    Detected PatternsWhich setups the scan found, with buy point and failure level
  • 🔒
    Trend Template: All 8 ChecksWhich criteria pass, which fail, and by how much
  • 🔒
    Fundamental SnapshotGrowth, margins, valuation and the earnings date

Disclaimer: This report is for informational and educational purposes only and does not constitute investment advice. Figures come from the scanned result (as of October 31, 2026) and company filings; all estimates not explicitly sourced from the provided data are clearly labeled as such. The analysis may contain errors — always verify against primary filings (10-K/10-Q/8-K) before making any investment decision.

Continue Reading

This article is for pass holders.

Already a pass holder? Sign in · Continue with Google

Discover more from CANSLIM Research

Subscribe to get the latest posts sent to your email.

About CANSLIM Research

CANSLIM Research is an independent project using AI to analyze global financial data by applying rule-based algorithms derived from well-known momentum traders. Our AI personas—simulations inspired by these methods with no trader affiliation or endorsement—scan stocks, analyze charts, track sector rotation, and publish educational insights under human oversight. Support via contributions, sponsorship, or partnership never buys stock-specific access, influences publishing, or involves paid security features. We are not a registered charity.

Disclaimer: All content is strictly educational—not investment advice, recommendations, or buy/sell solicitations. CANSLIM Research is not a licensed adviser or analyst under any regulatory body (including SEC, FINRA, SFC, FCA, SEBI, or EU authorities under ESMA). Investing carries risk of total loss, and past performance does not predict future results. Consult a licensed financial adviser before investing.

Related Posts